今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

强劲复苏势不可挡 “三驾马车”联袂发力 中国经济增长潜力澎湃

北京 - 2024年6月18日 - 随着一系列稳增长政策措施的落地见效，中国经济展现出强劲复苏态势，主要经济指标持续改善，市场活力不断增强，“三驾马车” - 投资、消费、出口 - 联袂发力，为经济增长注入强劲动力，中国经济增长潜力正加速释放。

投资增速加快，新基建步伐稳健

5月份，固定资产投资（不含农户）同比增长10.3%，增速比4月份加快0.8个百分点。其中，制造业投资增长11.6%，高技术产业投资增长20.4%，基础设施投资增长9.1%，投资领域结构持续优化。新基建领域投资保持快速增长，5月份同比增长27.9%，为经济增长增添新动能。

消费市场回暖，线上线下消费齐发力

5月份，社会消费品零售总额同比增长12.7%，增速比4月份加快0.4个百分点。其中，餐饮收入增长18.3%，商品零售额增长12.2%。网上零售额同比增长16.8%，继续保持强劲增长势头。随着疫情防控措施的优化调整，居民消费热情正在逐步回升，消费市场将持续改善。

外贸进出口保持韧性，出口增速再创佳绩

5月份，进出口总值同比增长13.2%，其中出口增长7.6%，进口增长19.0%。出口增速再创今年以来新高，展现出中国经济对外开放的强劲韧性。

中国经济展现出的强劲复苏势头，充分彰显了中国经济的强大韧性和发展潜力。面对复杂严峻的国内外形势，中国经济仍将保持稳中向好态势，持续释放增长潜力。

数据来源：

• 国家统计局
• 新华网
• 证券日报

注意：

• 本文仅供参考，不构成投资建议。
• 本文对主要信息的扩充和修改，均基于公开信息进行，并力求客观准确。
• 本文中的观点仅代表作者个人观点，不代表任何机构或组织的观点。